CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction
08 juil. 2024 07h00 HE
|
BioCardia, Inc.
CellProthera, and BioCardia [Nasdaq: BCDA], today announce success from a collaborative Phase II trial of ProtheraCytes for the treatment of AMI.
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
20 juin 2024 08h00 HE
|
Centogene NV
TUCSON, Ariz. and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path), a leader in forming collaborations that accelerate drug...
NBME collaborates with medical schools to advance workplace-based assessment in medical education
11 juin 2024 10h42 HE
|
NBME
PHILADELPHIA, June 11, 2024 (GLOBE NEWSWIRE) -- NBME is collaborating with five medical schools to explore the creation of a data-driven insights model to advance workplace-based assessment and data...
CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
14 mai 2024 08h30 HE
|
Centogene NV
CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical researchCompanies amend existing drug discovery partnership for Evotec to lead continued...
NBME Appoints New Vice President of Competency-Based Assessment
16 avr. 2024 10h55 HE
|
NBME
PHILADELPHIA, April 16, 2024 (GLOBE NEWSWIRE) -- NBME, a leading medical assessment company, has recently appointed Christopher Feddock, MD, to Vice President of Competency-Based Assessment (CBA) in...
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
19 mars 2024 06h30 HE
|
Centogene NV
Longstanding global partnership provides an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs) CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 19, 2024 ...
CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
25 janv. 2024 06h30 HE
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Jan. 25, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare...
NBME Revitalizes Grants Program to Enhance Assessment in Latin America
18 janv. 2024 13h46 HE
|
NBME
PHILADELPHIA, Jan. 18, 2024 (GLOBE NEWSWIRE) -- NBME renews the Latin America Grants Program to continue its commitment to advancing innovative approaches to medical education and enriching the...
CENTOGENE and Lifera, a Biopharma Company Owned by the PIF, Enter Strategic Collaboration – Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing and Securing CENTOGENE $30 Million Investment
27 juin 2023 07h30 HE
|
Centogene NV
Joint Venture (JV) combines CENTOGENE's global leadership in multiomics with local insight of Lifera, a biopharmaceutical company wholly-owned by the Public Investment Fund (PIF) based in RiyadhJV...
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
11 avr. 2023 06h30 HE
|
Centogene NV
The global market access and expansion partnership, initially established in 2015, aims to provide an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs) Diagnosis...